Erste Group Upgrades Novartis (NVS) to Buy, 'currently valued below the sector average despite the good growth prospects'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/16/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. DVLT
10. ADYYF

Go back to Erste Group Upgrades Novartis (NVS) to Buy, 'currently valued below the sector average despite the good growth prospects'

Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14

September 5, 2024 8:00 AM EDT

LEXINGTON, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Novartis AG (NYSE: NVS) has agreed to license a novel capsid generated from Voyagers TRACER capsid discovery platform for use in a gene therapy program against an undisclosed rare neurologic disease target. This capsid license is being granted pursuant to the agreement between Voyager and Novartis originally... More